Endorepellin, the C-terminal domain of perlecan, is a powerful angiogenesis inhibitor. To dissect the mechanism of endorepellin-mediated endothelial silencing, we utilized an antibody array against multiple tyrosine kinase receptors. Endorepellin caused a widespread reduction in phosphorylation of key receptors involved in angiogenesis and a concurrent increase in phosphatase activity in endothelial cells and tumor xenografts. These effects were efficiently hampered by function-blocking antibodies against integrin α2β1, the functional endorepellin receptor. The Src homology-2 protein phosphatase-1 (SHP-1) co-precipitated with integrin α2 and was phosphorylated in a dynamic fashion after endorepellin stimulation. Genetic evidence was provided by lack of an endorepellin-evoked phosphatase response in microvascular endothelial cells derived from integrin α2β1-/-mice and by response to endorepellin in cells geneticallyengineered to express the α2β1 integrin, but not in cells either lacking this receptor or expressing a chimera harboring the integrin α2 ectodomain fused to the α1 intracellular domain. siRNAmediated knockdown of integrin α2 caused a dose-dependent reduction of SHP-1. Finally, the levels of SHP-1 and its enzymatic activity were substantially reduced in multiple organs from α2β1-/-mice. Our results show that SHP-1 is an essential mediator of endorepellin activity and discover a novel functional interaction between the integrin α2 subunit and SHP-1.
Introduction
The development and maintenance of an efficient vascular system is vital for organ function and health in all higher organisms. Angiogenesis is abundant during fetal development but in the adult is a rare process mainly restricted to the female reproductive cycle and wound healing. However, deregulated angiogenesis is a prominent factor in many major diseases such as cancer, diabetes, and ischemia occurring after stroke. Controlled angiogenesis is achieved via interplay of pro and anti-angiogenic factors. Pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF), signal via their respective receptor tyrosine kinase (RTK) to stimulate endothelial cell migration and proliferation, whereas angiogenic inhibitors counteract these actions 1 . The list of reported negative regulators of angiogenesis is long, ever growing, and truly versatile.
Nevertheless, a common theme for many of them is that they are derived from limited proteolysis of extracellular matrix components and that they interact with integrin receptors 2 .
The angiostatic protein endorepellin, located within the C-terminus of the heparan sulfate proteoglycan perlecan, consists of three laminin globular (LG1-3) domains separated by four epidermal growth factor-like repeats 3 . Endorepellin exerts its activity via a non-canonical cationindependent binding of the LG3 domain to the α2 I-domain of the integrin α2β1 4-7 , a key receptor regulating angiogenesis [8] [9] [10] . This triggers a signaling cascade that leads to endothelial cell immobilization primarily due to disassembly of the actin cytoskeleton and disruption of focal adhesions 5 . Endorepellin efficiently retards tumor growth by targeting the tumor vasculature 11 .
Animals deficient in integrin α2β1 fail to respond to systemic delivery of recombinant endorepellin;
hence the integrin α2β1 receptor is indispensable for mediating endorepellin's anti-angiogenic effect in vivo 4 . Cathepsin L and BMP-1/Tolloid-like metalloproteases can release endorepellin and
LG3, respectively 6, 12 . The growing number of reports identifying LG3 in nearly all body fluids, including urine, blood and amniotic fluid, further strengthen the concept of an endogenous role for endorepellin LG3 in regulating angiogenesis and perhaps other biological processes [13] [14] [15] .
Many cellular processes such as survival, proliferation, differentiation, and migration are governed by RTK signaling. Upon binding with their specific ligand, RTKs dimerize and become autophosphorylated on multiple sites. The phosphorylation status of RTKs is tightly regulated by the activity of kinases and phosphatases. It has become apparent that integrins crosstalk with growth factor receptors to regulate cellular processes, such as endothelial cell migration and proliferation during angiogenesis 16 . One way of accomplishing this interaction is by integrinregulated recruitment of tyrosine phosphatases to growth factor receptors. Endothelial cell attachment to collagen I, which is primarily mediated by the α2β1 receptor, recruits the tyrosine phosphatase SHP-2 to the cytoplasmic tail of vascular endothelial growth factor receptor 2 (VEGFR2). This lowers the angiogenic response by inducing dephosphorylation of key tyrosine residues of the receptor 17 . On the other hand, activation of the integrin β3 subunit promotes
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From 4 angiogenesis by tethering SHP-2 to its cytoplasmic tail, which generates a net increase in VEGFR2 phosphorylation. Signaling by tissue inhibitor of metalloproteinase (TIMP) 2 via the integrin α3β1 dephosphorylates FGFR1 and VEGFR2 in endothelial cells 18 . Integrin α3β1 directly interacts with SHP-1 and TIMP2 stimulation shifts the phosphatase activity from integrin α3β1 to growth factor receptors 18 .
In the present work we demonstrate that endorepellin evokes a global RTK dephosphorylation via integrin α2β1-mediated activation of the tyrosine phosphatase SHP-1. We show that integrin α2β1 and SHP-1 are physically associated via the cytoplasmic domain of the integrin α2 subunit, and provide biochemical and genetic evidence for a key role of SHP-1 in mediating endorepellin's antiangiogenic activity.
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Methods

Antibodies, animals, cells, and other reagents
The following antibodies were used: anti-GAPDH (Advanced Immunochemical, Long Beach, CA), anti-SHP-1 (Millipore, Billerica, MA), anti-β-actin (Sigma, Saint Louis, MO), anti-integrin α2 Idomain (mAb 1998Z) and anti-integrin α5 (mAb 1969) (Millipore), anti-SHP-1, anti-SHP-2, anti-VEGFR2, anti-integrin α1 and α2 (Santa Cruz, Santa Cruz, CA), anti-integrin α1 (mAb 1969, Chemicon), anti-PY783-PLCγ1 and anti-PLCγ1 (Cell Signaling, Danvers, MA), and PY20 (BD Biosciences, Franklin Lakes, NJ). Secondary antibodies include: rhodamine-conjugated goat antirabbit IgG (Santa Cruz), HRP-conjugated goat anti-mouse and anti-rabbit (Jackson ImmunoResearchs, West Grove, PA), IR-680 goat anti-mouse, and IR-800CW goat anti-rabbit IgG (LI-COR, Lincoln, NE). Rhodamine-conjugated phalloidin, DAPI, and Na 3 VO 4 (Sigma), NSC-87877 (Calbiochem, San Diego, CA), rat tail collagen-I (BD Biosciences, Franklin Lakes, NJ) and VEGF 165 (R&D Systems, Minneapolis, MN) were used. Human umbilical vein endothelial cells (HUVECs) (Lifeline Cell Technology, Walkersville, MD), passage 1-5, were cultured on gelatin. The murine myogenic C2C12 and ureteric bud cells were maintained as described 19, 20 . HT-1080 were transfected with two siRNAs (Ambion, Foster City, CA) targeting integrin α2 as described 4 ,
HUVECs were transfected with siRNA cocktails targeting SHP-1 (sc29478), SHP-2 (sc-36488), or EphA2 (sc-29304) (Santa Cruz). Endorepellin was produced as previously described 3 . C57Bl/6
wild-type and α2 integrin subunit-deficient mice 21 were housed in the pathogen-free facility of Thomas Jefferson University in compliance with IACUC regulations.
Pan phospho-RTK array, immunoblots, immunostaining, and immunoprecipitation
HUVECs, grown in 100 μg/mL collagen-coated dishes, were serum-starved for 1 hour prior to endorepellin treatment. For integrin blocking experiments, cells were pre-incubated for 1 hour with various mAbs (10 μg/mL). Cells were lysed, protein extracted and RTK membranes probed following manufacturer's instructions (R&D Systems). Organs from C57Bl/6 wild-type and integrin α2β1-/-mice were snap-frozen in liquid nitrogen, homonogenized, and extracted in RIPA buffer.
Proteins were separated by sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto Nitrocellulose membranes (Bio-Rad, Hercules, CA). The blots were developed using either chemiluminesence or IR-labeled secondary antibodies and detected using Odyssey v2.1 (LI-COR, Lincoln, NE). Cells for immunostaining were fixed for 5 minutes in ice-cold methanol, blocked in 5% BSA-PBS and then reacted with mouse anti-human SHP-1 (Santa Cruz).
Images were acquired by confocal microscopy. Livers from wild-type and α2β1-/-mice were snapfrozen in liquid nitrogen, cryosectioned, fixed, and permeabilized in ice-cold acetone/0.2 % Triton-X100.
For
o C, and pre-cleared cell lysates were added to the beads for 18 hours at 4 o C. After extensive washing, the beads were boiled in reducing buffer and supernatants were separated by SDS-PAGE.
In vitro kinase assay
HUVECs were stimulated with 10 ng/ml VEGF 165 for 5 minutes, lysed in RIPA buffer and immunoprecipitated with anti-VEGFR2 antibody. The precipitates were washed in TBS-T and incubated with HUVEC lysates from cells treated with endorepellin for 0-10 minutes. The beads and lysates were incubated at 37 o C for 15 minutes, pelleted, washed, boiled and then processed for immunoblotting. The blots were probed with PY-20 and rabbit anti-human VEGFR2 and analyzed using Odyssey (LI-COR).
Tyrosine phosphatase and migration assays
Tyrosine phosphatase activity was measured using the Tyrosine-Phosphatase Assay kit (Promega, Madison, WI) following the manufacturer's protocol. Briefly, cell and tumor extracts pre-cleaned for phosphate were incubated with tyrosine phosphopeptides as substrate. The release of PO 4 was normalized on cell protein and expressed as pmol/mL/minute. Total phosphate content was determined by phosphate standards run in parallel. Phosphopeptide-specific activity was calculated by subtracting the nonspecific activity. The activity of SHP-1 was assessed on SHP-1
immunoprecipitates. Tumor xenograft, adhesion, migration and cytoskeleton disassembly assays were done as previously described 4 . For UB and C2C12 cell migration, self-conditioned media were used as a chemoattractants. For PLCγ1 phosphorylation assays, HUVECs were serumstarved for 1 hour with or without the addition of Na 3 VO 4 and NSC-87877, after which 10 ng/mL VEGF 165 , in combination with 25 nM endorepellin, or 25 nM endorepellin alone was added for 5 minutes.
Statistical analyses
All data are expressed as means ± SEM and were statistically analyzed using Student's t test or paired t test with the Sigma-Stat software 10.0 (SPSS-10). Probabilities less than .05 were considered statistically significant. 
Results
Endorepellin evokes global dephosphorylation of receptor tyrosine kinases in endothelial cells
To discover novel pathways affected by endorepellin in endothelial cells, we screened for changes in the phosphorylation status of RTKs following endorepellin stimulation using phosphor-RTK arrays. We found that endorepellin caused a global dephosphorylation of RTKs. This effect was prominent already after a 5-minute treatment and sustained for up to 30 minutes ( Figure 1A and Table 1 ). Notably, functional block of the integrin α2β1 receptor with the mAb 1998Z abrogated the endorepellin-evoked RTK dephosphorylation ( Figure 1B and Table 1 ). On the contrary, blocking integrin α5β1 did not affect the endoprellin response ( Figure S1 ).
The rapid dephosphorylation in endothelial cells suggested that endorepellin might induce the enzymatic activity of a tyrosine phosphatase. Thus, we investigated endorepellin-evoked changes in the general tyrosine phosphatase activity in HUVECs grown on collagen. The results showed a rapid and dynamic profile of total tyrosine phosphatase activity, which peaked at 5 minutes, and returned to basal levels after 30 minutes (Figure 2A ). This process was completely blocked by the general tyrosine phosphatase inhibitor Na 3 VO 4 ( Figure 2A ).
The integrin α2β1 is required for endorepellin induction of tyrosine phosphatase activity
To address the genetic requirement of integrin α2β1 for the endorepellin-induced phosphatase response, we isolated lung microvascular endothelial cells from wild-type mice and from mice with a targeted disruption of either integrin α1 22 or α2 21 gene, thereby lacking a functional integrin α1β1 or α2β1 gene, respectively. Following a 5-minute exposure to recombinant human endorepellin (25 nM) there was a ~40% increase in tyrosine phosphate activity in both wild-type and integrin α1β1-/-microvascular endothelial cells but no changes in the integrin α2β1-/-cells ( Figure 2B ).
To ascertain that the elicited phosphatase activation was indeed responsible for the global RTK dephosphorylation, we performed a non-radioactive in vitro kinase assay. Phosphorylated VEGFR2 was immunoprecipitated and treated for 15 minutes with HUVEC lysates collected after progressive endorepellin exposure. The results showed a dynamic and significant decrease in the VEGFR2 phosphorylation ( Figure 2C ). This indicates that the endorepellin-evoked phosphatase activity translates into dephosphorylation of RTKs in agreement with the phospho-RTK arrays.
To further establish that the unresponsiveness of the α2β1-/-cells was due to lack of this receptor and not to off-target consequences of gene deletion, we utilized: (i) murine myogenic C2C12 cells which, lack classical collagen-binding integrins ( Figure S2 ) and therefore attach poorly to collagen 19 , and (ii) C2C12 stably expressing either the human integrin α2 (α2β1+) 19 or α1 subunit (α1β1+) 23 . We determined that α1β1+ and α2β1+ C2C12 expressed their transgenes at comparable levels ( Figure S2B ). Following a 5-minute challenge with recombinant endorepellin, subunit is fundamental for the endorepellin-mediated boost in tyrosine phosphatase activity and rule out the possibility that the phosphatase response is solely dependent on the integrin β1 subunit or the integrin α-chain common motif.
Integrin α2β1 is physically and functionally linked to the tyrosine phosphatase SHP-1
The rapid increase in tyrosine phosphatase activity suggested that the integrin α2β1 receptor might be directly linked to a tyrosine phosphatase. To this end, cell lysates from HUVECs stimulated with endorepellin up to 30 minutes were immunoprecipitated with antibodies against the integrin α2 subunit. HUVECs grown on collagen strongly expressed integrin α2 ( Figure S2C ). Two different rabbit polyclonal antibodies were used in the immunoprecipitation analyses and both antibodies coimmunoprecipitated a ~70-kDa band detected with antibodies against phosphotyrosine ( Figure 3A ).
Because we recently discovered that endorepellin activates the ~70-kDa tyrosine phosphatase SHP-1 in collagen-stimulated platelets 24 , we probed the immunoprecipitated with an antibody specific for SHP-1. We found that the 70-kDa band was indeed SHP-1 ( Figure 3A ) and that SHP-1 underwent a rapid and dynamic change in both association with the integrin α2 subunit ( Figure 3B ) and in phosphorylation ( Figure 3C ). Moreover, we were able to pull down the α2-subunit with an
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Similar results were obtained with a different anti-SHP-1 antibody (not shown). Total SHP-1 was phosphorylated in the same dynamic fashion as that of the integrin α2-associated fraction, albeit at a lower level ( Figure 3D ).
Integrin α subunits bear sequence similarities in their cytoplasmic juxta-membrane region that diverge into unique motives closer to their C-termini. To determine whether the interaction of SHP-1 with the integrin α2 was rather special for this subunit we performed co-immunoprecipitation assays with C2C12 cells expressing either α1β1 or α2β1. In the α1β1+ cells integrin α1 and SHP-1 did not co-precipitate, whereas in the α2β1+, SHP-1 and integrin α2 readily co-precipitated ( Figure S4 ). This suggests that the interaction with SHP-1 is not general for all α subunits but a more specialized event for the α2 subunit.
Having established a physical link between SHP-1 and the integrin α2β1, we examined if SHP-1 could account for the increase in phosphatase activity following endorepellin treatment. We immunoprecipitated SHP-1 from endorepellin-stimulated HUVECs and measured the ability of the immunoprecipitated proteins to dephosphorylate a tyrosine peptides. SHP-1 was activated in a transient manner ( Figure 3E ), mimicking the kinetics of total tyrosine phosphatase activity and the phosphorylation of integrin α2-linked SHP-1. To test whether the endorepellin-evoked SHP-1 activation was a more general phenomenon, we extended our studies to include the α2β1-carrying C2C12 and ureteric bud cells. SHP-1 was rapidly activated by endorepellin in cells expressing fulllength integrin α2 ( Figure 3F,G) .
Collectively, these results show that SHP-1 activation triggered by a specific interaction between soluble endorepellin and the integrin α2β1 receptor contributes significantly to the overall increase in tyrosine phosphatase activity in endothelial cells and in cells de novo expressing this integrin.
Endorepellin signaling induces translocation of SHP-1 into the nuclei
SHP-1 can translocate into the nuclei 25 where it can regulate transcription of early response genes 26 . We tested wild-type and integrin α1-and α2-transfected C2C12 cells, which show high expression of SHP-1. Endorepellin caused a rapid SHP-1 translocation from the plasma membrane to the nuclei in α2β1+ cells ( Figure S5A,B) . In contrast, no differences in SHP-1 subcellular distribution were seen in either wild-type or α1β1+ cells ( Figure S5A ). Imaging quantification revealed a statistically-significant shift of SHP-1 to the nuclei in integrin α2β1+ cells after addition of endorepellin ( Figure S5C , P<.001). In addition, biochemical analyses of separated cytoplasmic and nuclear fractions also revealed this shift ( Figure S5D ,E). Thus, endorepellin evokes not only SHP-1 phosphatase activity but also its translocation into the nuclei, where it presumably will affect transcriptional activity of early response genes.
SHP-1 expression is stabilized by integrin α2β1
In preliminary studies, we noticed that α2β1+ C2C12 cells showed stronger expression of SHP-1 than either wild-type or α1β1+ cells. We discovered that de novo expression of the integrin α2 subunit caused a marked increase in SHP-1 protein levels ( Figure 4A ). In contrast, introduction of the α1 subunit did not noticeably change SHP-1 content ( Figure 4A ). These changes were unique for SHP-1, as SHP-2 was not altered ( Figure 4A ), and were not due to clonal selection insofar as the transgenic cells are polyclonal in nature.
To validate the functional role of the integrin α2β1, we utilized a gene targeting approach using validated small interfering RNAs (siRNAs) to knockdown the α2 subunit in HT-1080 cells, a fibrosarcoma cell line that expresses high levels of integrin α2β1 4 . Expression of the integrin α2-subunit was efficiently blocked by the siRNAs targeting two different regions of the α2 mRNA in a dose-dependent manner ( Figure 4B ). Importantly, SHP-1 levels concurrently declined in these cells ( Figure 4B ), suggesting that the presence of the integrin α2β1 is required for maintaining the cellular levels of SHP-1. Knockdown of EphA2, a receptor that was strongly dephosphorylated in the initial RTK arrays, had no affect on SHP-1 levels ( Figure 4B ).
The finding that SHP-1 was dependent on the physical presence of integrin α2β1 prompted us to analyze the requirement of integrin α2β1 for SHP-1 expression in whole organs from wild-type and α2β1-/-mice. SHP-1 levels were significantly (P<.05) reduced by 30-60 % in the integrin α2β1-/-organs ( Figure 4C,D) . This was also true for the microvascular endothelial cells isolated from the lungs of integrin α2β1-/-mice ( Figure 4C ). Again, SHP-2 levels were not changed in these mice, indicating a unique interaction between integrin α2 and SHP-1.
Liver displayed a specific staining for integrin α2 ( Figure S6A,B) . Further, SHP-1 colocalized with integrin α2 at the cell surface ( Figure S6C-E) . Free cytoplasmic SHP-1 exists predominantly in a folded "inactive" conformation 26 . Thus, we hypothesized that depletion of a potential interaction partner such as the integrin α2 subunit could potentially cause a loss of SHP-1 pool associated with the plasma membrane. Confocal analysis showed that SHP-1 was located in hepatocyte nuclei, in accordance with previous studies 27 , and further revealed a loss of plasma membraneassociated SHP-1 in α2β1-/-livers ( Figure S6F,G) . Accordingly, we measured the tyrosine phosphatase activity in immunoprecipitated SHP-1 from wild-type and integrin α2β1-/-hepatic tissue. In integrin α2β1 null livers (n=3) SHP-1 activity was reduced by ~65% when compared to integrin α2β1-competent livers ( Figure 4E ).
Our results suggest that SHP-1/α2β1 interaction is vital for maintaining both the physical presence and the functionality of the phosphatase.
Inhibition of tyrosine phosphatases blocks endorepellin angiostatic activity
Next, we downregulated SHP-1 expression in HUVECs using a mixture of three validated siRNAs directed towards human SHP-1 ( Figure 5A ). In VEGF 165 -driven migration assays, endorepellin significantly inhibited endothelial cell migration through collagen ( Figure 5C , P<.001). Endorepellin activity was also abrogated by Na 3 VO 4 (1 μM), a general tyrosine phosphatase inhibitor, and NSC-87877 (1 μM), a specific inhibitor of SHP-1/2 activity 28 ( Figure 5C ). Preincubation of HUVECs with either Na 3 VO 4 or NSC-87877 (both at 1 μM) completely blocked endorepellin-evoked phosphorylation of SHP-1 (data not shown). In contrast, PP2-mediated block of Src, a small tyrosine kinase implicated in integrin-mediated activation of tyrosine phosphatases and phosphorylation of FAK, did not affect the endorepellin-induced block of migration (data not shown). Knockdown of SHP-2 ( Figure 5B ) caused a general delay in endothelial cell migration in line with previous reports 29 , but did not dampen the response to endorepellin ( Figure 5D ).
To further prove a role for SHP-1 in endorepellin biological activity, we conducted an actin disassembly assay using HUVECs. A short treatment with endorepellin (100 nM) caused a rapid disassembly of actin cytoskeleton as visualized by phalloidin staining ( Figure 5E ). Pre-incubation with either Na 3 VO 4 or NSC-87877 (both at 1 μM) rendered the cells resistant to endorepellin's activity ( Figure 5E ). Quantification of multiple experiments showed that both tyrosine phosphatase inhibitors completely blocked the activity of endorepellin ( Figure 5F , P<.001).
Collectively, our data corroborate the hypothesis that SHP-1 activity is crucial for endorepellinevoked endothelial cell silencing.
Endorepellin-evoked phosphatase activity modulates RTK downstream signaling
Given endorepellin's promotion of global RTK dephosphorylation, we focused on VEGF/VEGFR2 signaling pathway by examining PLCγ1, a direct downstream target of VEGFR2. When HUVECs were treated for 5 minutes with VEGF 165 (10 ng/mL), a robust phosphorylation of PLCγ1 at Tyr783 was observed ( Figure 6A ). However, concurrent treatment with endorepellin (25 nM) significantly reduced PLCγ1 phosphorylation by >50%. Prior silencing of SHP-1 by either Na 3 VO 4 or NSC-87877, completely blocked endorepellin-evoked reduction in PLCγ1 phosphorylation ( Figure 6A ,B,
P<.001).
To determine the generality of endorepellin engagement of SHP-1 on tyrosine phosphorylation, we analyzed the total tyrosine phosphorylation status of endothelial cells following a 5-minute exposure to endorepellin. Endorepellin globally but specifically reduced tyrosine phosphorylation and these effects could be blocked by Na 3 VO 4 or NSC-87877 ( Figure S7A ,B).
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Endorepellin activates SHP-1 in tumor xenografts in vivo
We previously showed that endorepellin functions as an antitumor agent by specifically suppressing tumor angiogenesis 4, 11 . To translate our in vitro findings into a more clinically-relevant setting, we inoculated C57Bl/6 mice with syngeneic Lewis lung carcinoma cells. The mice were treated with PBS or endorepellin by intraperitoneal injections on alternate days after the tumors became palpable. Endorepellin significantly reduced tumor burden ( Figure 7A ) and microvascular density ( Figure 7B-D) . Notably, endorepellin evoked a significant increase in total tyrosine phosphatase activity in the tumor xenografts of wild-type mice but failed to do so in the tumor xenografts generated in integrin α2β1-/-mice ( Figure 7E ). Immunoprecipitated SHP-1 from tumor lysates showed a significant increase in tyrosine phosphorylation from tumors that had received endorepellin ( Figure 7F ,G). These findings indicate that the host endothelial cells are key mediators of the phosphatase response and that endorepellin is able to activate SHP-1 in vivo.
Discussion
In the search for novel pathways affected by endorepellin, we discovered that endorepellin provokes a global dephosphorylation of several RTKs. This effect is dependent on the presence of the integrin α2β1, the principal perlecan receptor on endothelial cells 4 . RTK phosphorylation levels after ligand engagement are determined by autophosphorylation or phosphorylation of the receptor by other protein kinases and by dephosphorylation via tyrosine phosphatases. Integrins in general 16 , and collagen-binding integrins in particular 17, 30 regulate tyrosine phosphatases.
Endorepellin causes a rapid activation of the tyrosine phosphatase SHP-1. SHP-1 was first considered to be a phosphatase of hematopoietic cells, but it is now known that its expression is wider than originally proposed 26 and that SHP-1 acts as a modulator of blood vessel growth 18, 31, 32 .
In endothelial cells, SHP-1 readily co-immunoprecipitates with integrin α2 and, upon endorepellin We previously reported that, in endothelial cells, endorepellin evokes a rapid increase in the intracellular cAMP levels which in turn activates cAMP-dependent protein kinase A (PKA), a required pathway for endorepellin's angiostatic activity 5 . The endorepellin-evoked activity is in sharp contrast to endothelial response to collagen I insofar as collagen I-induced capillary morphogenesis is mediated by an integrin α2β1-dependent suppression of intracellular cAMP levels and PKA activity 37 . TIMP-2 also induces a rapid and substantial increase in cAMP levels and concurrent activation of cAMP-dependent PKA in microvascular endothelial cells, fibroblasts, as well as in a number of transformed cells 33, 36, 38 . Interestingly, SHP-1 has been indirectly linked to PKA activation as tyrosine phosphatases are crucial for TIMP-2 induced phosphorylation of PKA targets 33 . PKA can phosphorylate serine residues at the C-terminus of SHP-1; this reduces the activity of SHP-1, thereby creating a potential auto-regulatory loop 32, 39 a mechanism that could potentially occur in the case of endorepellin and TIMP2 signaling. The results from the α2-chimera studies indicate that a unique motif in the cytoplasmic tail of integrin α2 is crucial for interaction with SHP-1, a concept strengthened by the fact that no tyrosine phosphorylation-mediated activity is attributed to the integrin β1 chain in endothelial cells grown on collagen 17 . The closely related integrin α1 subunit activates the tyrosine phosphatase TCPTP when attached to collagen 30, 41 . A short and unique sequence at its C-terminus binds the N-terminal part of TCPTP, thereby relieving the phosphatase out of its inactive conformation 30 . Free SHP-1 is in a similar auto-inhibited conformation, with its N-terminus SH-2 domain folded over the catalytic domain via a charge-dependent interaction 26, 42 . The C-terminal SH-2 domain is in this closed conformation exposed and could function as an antenna searching for motives that activate the phosphatase. Binding of the C-terminal SH-2 domain to a target distorts the closed conformation, which weakens the auto-inhibitory connection 42 . The precise nature of the interaction between integrin α2 and α3 with SHP-1 is not known. However, in analogy to the TCTPT interaction with integrin α1, SHP-1 could recognize a common motif in the integrin α2 and α3 cytoplasmic tails.
Alignment of integrin α2 with integrin α3B, the integrin α3 isoform expressed in the vein endothelial cells used for the TIMP-2 studies, shows similarities in their non-conserved C-terminal sequences ( Figure S8 ). Both contain an arginine two amino acid residues upstream of a tyrosine residue, a polar residue one amino acid downstream followed by a methionine. Interestingly, this sequence matches the consensus sequence for peptides that bind the SHP-1 C-terminal SH2 domain 43 .
Nuclear translocation of SHP-1 is cell-context dependent. In non-hematopoietic cells, SHP-1 shows more nuclear localization than hematopoietic cells 26 . However, after TIMP-1 stimulation of germinal center B cells SHP-1 is translocated to the nucleus 25 . This is in agreement with our finding showing that endorepellin stimulation leads to nuclear translocation of SHP-1 in the myogenic α2β1+C2C12. Nuclear SHP-1 could dephosphorylate key transcription factors, such as STAT3 25, 26 but the precise impact of nuclear SHP-1 remains to be clarified.
A novel result of our study was the decline of SHP-1 levels in liver, kidney and spleen from α2β1-null animal, in addition to the pulmonary microvascular endothelial cells. Moreover, tyrosine phosphatase activity from SHP-1 immunoprecipitated from the liver of α2β1-/-mice was also significantly reduced. These results suggest that α2β1 is necessary to stabilize SHP-1, perhaps by prolonging its half-life. Both integrin α2β1-/-44 and the viable Shp-1-/-mice, known as moth-eaten mice 45 exhibit impairment of the immune system. The α2β1-null mice display reduced neutrophil recruitment upon peritonitis induced by Listeria monocytogenes or the fungal polysaccharide zymosan 44 . The defective response to Listeria was considered to be due to crosstalk between integrin α2β1 and Met, the receptor for hepatocyte growth factor and the Listeria pathogen internalin B 46 . Zymosan is not a known ligand for Met, but interacts with the Toll-like receptor 2 (TLR-2) 47 , which in turn physically associates with SHP-1 48 . Although SHP-1 has been mainly implicated as negative modulator of cytokine signaling, it can also act as a positive factor for various cytokines, including TNF-α, interferon α, interleukin (IL) 4 and 10 49 and TLR-3 and -4 induced production of interferon β 50 . Interestingly, integrin α2β1-deficient mice show no increase in the IL-6 release after zymosan stimulation and Listeria-infected α2β1-/-mice experience additional impairment in IL-β and TNF-α excretion 44 . In light of our findings, the malfunctioning immune response to fungi and bacteria in the integrin α2β1-/-mice could be in part explained by concurrent decrease in total SHP-1 levels and phosphatase activity.
Notably, the α2β1 null mice show an enhanced angiogenic response during wound healing 7 and tumor xenograft development 4, 46 . This anomalous "hyperangiogenic phenotype" could also be in part attributed to a dual loss of a receptor for endorepellin and to a decline in SHP-1 levels and phosphatase activity. This is further supported by a study showing that siRNA-mediated knockdown of SHP-1 accelerates angiogenesis in a rat model of hind limb ischemia 31 .
In summary, we have shown that endorepellin activates the tyrosine phosphatase SHP-1 via the integrin α2β1 receptor. This finding substantially illuminates the mechanism of action of endorepellin in inducing endothelial cell silencing, and is beneficial to further our understanding of angiogenesis in general and for the development of novel therapeutics for diseases where controlled de novo blood vessel formation is of importance. 
